Sign In
Buy ADAG
$3.98
+0.140 (+3.65%)
At Close: Jun 23, 2026
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
01:00pm, Friday, 05'th Jun 2026
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Adagene (ADAG) This Year?
10:41am, Tuesday, 02'nd Jun 2026
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
05:08pm, Tuesday, 19'th May 2026
Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Step
Adagene to Participate in Two Upcoming Investor Conferences
08:30am, Tuesday, 12'th May 2026
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Growth in Short Interest
03:13am, Sunday, 26'th Apr 2026
Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 411,325
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively
Adagene Looks Attractive With ADG126 And Validating Partnerships
02:08pm, Thursday, 16'th Apr 2026
Adagene is essentially a single-asset bet on ADG126, which is a masked anti-CTLA-4 antibody designed to improve tolerability in immuno-oncology. ADG126's upcoming AACR 2026 updates are likely the bigg
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
07:00am, Tuesday, 14'th Apr 2026
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and deve
CytomX Therapeutics (NASDAQ:CTMX) & Adagene (NASDAQ:ADAG) Financial Comparison
02:17am, Sunday, 05'th Apr 2026
Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two busi
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
07:10am, Thursday, 02'nd Apr 2026
SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement o
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
05:00pm, Wednesday, 01'st Apr 2026
In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months,
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 44.6%
01:13am, Saturday, 28'th Mar 2026
Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 74,0
SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based
